MAGE A10 TCR: Phase I/II started

Adaptimmune began an open-label, dose-escalation, international Phase I/II trial to evaluate IV MAGE A10 TCR in up to 32 patients with the HLA-A*0201 and HLA-A*0206 alleles and NSCLC positive for MAGE...